- Home
- Industry Reports
- Healthcare
- Medical Devices
- North America Cancer Immunotherapy Market – Growth & Forecast (2023 – 2030)
Immunotherapy has potential to treat cancer and prevent future deuteriation by activating the immune system to recognise and kill the cancer cells. Several approaches have been developed to turn the immune system against cancer. Car T-cell therapy also Known as adoptive cell transfer therapy used to treat blood cancers, TCR therapy, TIL therapy and some others are used to treat cancer.
North America Cancer Immunotherapy Market Segments Size & Growth:
North America Cancer Immunotherapy Market is estimated to increase by an $XX billion by 2024 at a CAGR of XX%. Augmenting adoption of immunotherapy over other treatment options and increased development of bioinformatic tools enhancing drug development process are the key drivers accelerating to growth. Rising incidence of cancer and growth in adoption of advanced therapeutics are major drivers accelerating the overall market growth. High cost of medications hindering the market growth. Growth in clinical trials against several types of therapies is one of the major important opportunities for the market. Increasing R&D in cancer immunotherapy is resulting in the introduction of advanced treatment options that are more effective and efficient.
North America Cancer Immunotherapy Market Segments Share:
Based on production, cancer immunotherapy is further divided into checkpoint Inhibitors, monoclonal antibodies, cell therapies, vaccines, and immunomodulators. Monoclonal antibodies are class of antibodies produced by identical hybridoma cells. With the help of various advanced and powerful technologies which are being used in areas of biochemistry, biology, biotechnology, medical sciences, and immunology. These are sub-bodies further divided into conjugated monoclonal antibodies, bispecific monoclonal antibodies, and naked monoclonal antibodies. Advancements in monoclonal antibodies include phase display, hybridoma technology, single B cell amplification and many advancements. Vaccines are further divided into tumour cell vaccines, Allogeneic tumour cell vaccines, DC vaccines, peptide-based cancer vaccines, genetic vaccines and some other.
Application segment includes colorectal cancer, melanoma, prostate cancer, lung cancer, head & neck cancer, multiple myeloma, breast cancer and others. Lung cancer is estimated to have the largest share during the forecasting period. The major driver includes increasing incidences of lung cancer these days. About 85% of deaths nowadays are happening due to smoking. In the U.S more than one million people are diagnosed with cancer every year. Rising demand for advanced treatment options is also a major driver for the market growth.
Cancer immunotherapy by the end user is further divided into hospitals, clinics, and some others. Hospitals segment is projected to have the highest market size over 2018-2024. Increase in investments in the healthcare sector and numerous increase in usage of the immunotherapy drugs in different hospitals are accelerating the cancer immunotherapy market growth.
Based on geography, cancer immunotherapy is segmented into North America, South America, Europe, Asia Pacific and the Middle East and Africa. North America is estimated to have largest market size during the forecasting period owing to the growth in patient population, augmenting demand for the technologies for the treatment of cancer and initiatives by the government mostly in the countries like U.S, Mexico, and Canada.
North America Cancer Immunotherapy Market Trends:
- Cyramza was launched by the Elli and Lilly company which is used for the treatment of metastatic non-small cell lung cancer.
- Tagrisso is a new potential care for the patient specifically adults which is used to treat non-small cell drug launched by AstraZeneca plc in June 2017.
- AZACTAM (aztreonam injection) used for the treatment of cancer and launched by Bristol-Myers Squibb Company
North America Cancer Immunotherapy Market Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial analysis with major competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- AstraZeneca Plc
- ELI Lilly and Company
- Bristol-Myers Squibb
- Bayer AG
- Novartis International AG
- Hoffmann-La Roche Ltd
Along with these companies, there were many other companies considered/cited in the report while analysing the Global electric vehicle charging equipment market. These companies hold substantial share-owning to the nature of the industry whereas rest of the market shares are marginal chunks to regional and local level manufacturers. Other players have considerable presence owing to its robust brand image, geographical reach and strong customer base
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2Porter’s Five Force Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1. Drivers
4.1.1 Growth in adoption of immunotherapy over other treatment options
4.1.2 Increased development of bioinformatic tools enhancing drug development process
4.2 Restraints
4.2.1 Cost issues
4.3 Opportunities
4.3.1 Rising number of clinical trials against many types of cancers in immunotherapy
4.3.2 Increased growth prospects in developing countries
4.4 Challenges
4.4.1 Limited funds for the initiation of clinical trials
4.4.2 Complexity of cancers
Chapter 5 North America Cancer Immunotherapy Market – By Production
5.1 Checkpoint Inhibitors
5.2 Monoclonal Antibodies
5.3 Cell Therapies
5.4 Immunomodulators
Chapter 6 North America Cancer Immunotherapy Market – By Application
6.1 Colorectal Cancer
6.2 Melanoma
6.3 Prostate Cancer
6.4 Lung Cancer
6.5 Head & Neck Cancer
6.6 Multiple Myeloma
6.7 Breast Cancer
6.8 Others
Chapter 7 North America Cancer Immunotherapy Market – By End-user
7.1 Hospitals
7.2 Clinics
7.3 Others
Chapter 8 North America Cancer Immunotherapy Market – By Geography
8.1 Introduction
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
Chapter 9 North America Cancer Immunotherapy Market – Company Profiles
9.1 AstraZeneca Plc
9.2 ELI Lilly and Company
9.3 Bristol-Myers Squibb
9.4 Bayer AG
9.5. Novartis International AG
9.6 F. Hoffmann-La Roche Ltd
9.7 Janssen Global Services, LLC (Johnson and Johnson)
9.8 Pfizer Inc
9.9 Merck & Company, Inc.
9.10 Amgen Inc.
Chapter 10 North America Cancer Immunotherapy Market – Competitive Landscape
10.1. Market Share Analysis
10.2. Strategies Adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
Chapter 11 Market Insights
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
Chapter 12 Appendix
12.1 List of Tables
12.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Regional Report
$2,160.00 – $7,200.00
- EUR: €1,986.21 - €6,620.69
- INR: ₹179,975.17 - ₹599,917.24
- AED: د.إ7,927.20 - د.إ26,424.00
- GBP: £1,709.03 - £5,696.77
Description
Regional Reports
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
Immunotherapy has potential to treat cancer and prevent future deuteriation by activating the immune system to recognise and kill the cancer cells. Several approaches have been developed to turn the immune system against cancer. Car T-cell therapy also Known as adoptive cell transfer therapy used to treat blood cancers, TCR therapy, TIL therapy and some others are used to treat cancer.
North America Cancer Immunotherapy Market Segments Size & Growth:
North America Cancer Immunotherapy Market is estimated to increase by an $XX billion by 2024 at a CAGR of XX%. Augmenting adoption of immunotherapy over other treatment options and increased development of bioinformatic tools enhancing drug development process are the key drivers accelerating to growth. Rising incidence of cancer and growth in adoption of advanced therapeutics are major drivers accelerating the overall market growth. High cost of medications hindering the market growth. Growth in clinical trials against several types of therapies is one of the major important opportunities for the market. Increasing R&D in cancer immunotherapy is resulting in the introduction of advanced treatment options that are more effective and efficient.
North America Cancer Immunotherapy Market Segments Share:
Based on production, cancer immunotherapy is further divided into checkpoint Inhibitors, monoclonal antibodies, cell therapies, vaccines, and immunomodulators. Monoclonal antibodies are class of antibodies produced by identical hybridoma cells. With the help of various advanced and powerful technologies which are being used in areas of biochemistry, biology, biotechnology, medical sciences, and immunology. These are sub-bodies further divided into conjugated monoclonal antibodies, bispecific monoclonal antibodies, and naked monoclonal antibodies. Advancements in monoclonal antibodies include phase display, hybridoma technology, single B cell amplification and many advancements. Vaccines are further divided into tumour cell vaccines, Allogeneic tumour cell vaccines, DC vaccines, peptide-based cancer vaccines, genetic vaccines and some other.
Application segment includes colorectal cancer, melanoma, prostate cancer, lung cancer, head & neck cancer, multiple myeloma, breast cancer and others. Lung cancer is estimated to have the largest share during the forecasting period. The major driver includes increasing incidences of lung cancer these days. About 85% of deaths nowadays are happening due to smoking. In the U.S more than one million people are diagnosed with cancer every year. Rising demand for advanced treatment options is also a major driver for the market growth.
Cancer immunotherapy by the end user is further divided into hospitals, clinics, and some others. Hospitals segment is projected to have the highest market size over 2018-2024. Increase in investments in the healthcare sector and numerous increase in usage of the immunotherapy drugs in different hospitals are accelerating the cancer immunotherapy market growth.
Based on geography, cancer immunotherapy is segmented into North America, South America, Europe, Asia Pacific and the Middle East and Africa. North America is estimated to have largest market size during the forecasting period owing to the growth in patient population, augmenting demand for the technologies for the treatment of cancer and initiatives by the government mostly in the countries like U.S, Mexico, and Canada.
North America Cancer Immunotherapy Market Trends:
- Cyramza was launched by the Elli and Lilly company which is used for the treatment of metastatic non-small cell lung cancer.
- Tagrisso is a new potential care for the patient specifically adults which is used to treat non-small cell drug launched by AstraZeneca plc in June 2017.
- AZACTAM (aztreonam injection) used for the treatment of cancer and launched by Bristol-Myers Squibb Company
North America Cancer Immunotherapy Market Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial analysis with major competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- AstraZeneca Plc
- ELI Lilly and Company
- Bristol-Myers Squibb
- Bayer AG
- Novartis International AG
- Hoffmann-La Roche Ltd
Along with these companies, there were many other companies considered/cited in the report while analysing the Global electric vehicle charging equipment market. These companies hold substantial share-owning to the nature of the industry whereas rest of the market shares are marginal chunks to regional and local level manufacturers. Other players have considerable presence owing to its robust brand image, geographical reach and strong customer base
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2Porter’s Five Force Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1. Drivers
4.1.1 Growth in adoption of immunotherapy over other treatment options
4.1.2 Increased development of bioinformatic tools enhancing drug development process
4.2 Restraints
4.2.1 Cost issues
4.3 Opportunities
4.3.1 Rising number of clinical trials against many types of cancers in immunotherapy
4.3.2 Increased growth prospects in developing countries
4.4 Challenges
4.4.1 Limited funds for the initiation of clinical trials
4.4.2 Complexity of cancers
Chapter 5 North America Cancer Immunotherapy Market – By Production
5.1 Checkpoint Inhibitors
5.2 Monoclonal Antibodies
5.3 Cell Therapies
5.4 Immunomodulators
Chapter 6 North America Cancer Immunotherapy Market – By Application
6.1 Colorectal Cancer
6.2 Melanoma
6.3 Prostate Cancer
6.4 Lung Cancer
6.5 Head & Neck Cancer
6.6 Multiple Myeloma
6.7 Breast Cancer
6.8 Others
Chapter 7 North America Cancer Immunotherapy Market – By End-user
7.1 Hospitals
7.2 Clinics
7.3 Others
Chapter 8 North America Cancer Immunotherapy Market – By Geography
8.1 Introduction
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
Chapter 9 North America Cancer Immunotherapy Market – Company Profiles
9.1 AstraZeneca Plc
9.2 ELI Lilly and Company
9.3 Bristol-Myers Squibb
9.4 Bayer AG
9.5. Novartis International AG
9.6 F. Hoffmann-La Roche Ltd
9.7 Janssen Global Services, LLC (Johnson and Johnson)
9.8 Pfizer Inc
9.9 Merck & Company, Inc.
9.10 Amgen Inc.
Chapter 10 North America Cancer Immunotherapy Market – Competitive Landscape
10.1. Market Share Analysis
10.2. Strategies Adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
Chapter 11 Market Insights
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
Chapter 12 Appendix
12.1 List of Tables
12.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.